SB's Factive not approved

Published: 3-Feb-2001


SmithKline Beecham has received a non-approval letter from the FDA for its antibiotic gemifloxacin mesylate (Factive). Although disappointed with the decision, the company says it still intends to pursue the product.

See more

You may also like

Manufacturing
DFE Pharma to showcase its Continuous Manufacturing Platform at CPHI Milan 2026

DFE Pharma to showcase its Continuous Manufacturing Platform at CPHI Milan 2026

Read more
The platform supports pharmaceutical companies in developing, evaluating and optimising formulations and processes for continuous manufacturing

Trending Articles

  1. Bausch and Lomb hit with FDA Warning Letter for persistent microbial contamination The regulator cited persistent out-of-limit microbial recoveries in ISO 5 areas, deficiencies in aseptic processing and airflow controls and an ineffective quality system at Bausch and Lomb's Tampa manufacturing facility
  2. Loftware and RiseNow partner to strengthen supply chain traceability and compliance in healthcare settings The alliance pairs Loftware's SAP-integrated product identification platform with RiseNow's procurement and supply chain advisory services, delivering end-to-end track-and-trace capabilities for regulated industries where audit readiness and patient safety are critical
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Beyond the barcode: building flexible, connected and patient-focused pharmaceutical packaging supply chains Pharmaceutical packaging has always performed a critical function. It protects the product, communicates essential information and enables a medicine to move safely through the supply chain. However, the demands now being placed on packaging operations extend far beyond these established responsibilities
  4. ChargePoint Technology launches Actis aseptic transfer system to deliver isolator-level sterility in a compact unit The automated steam-sterilisable system bypasses the "ring of concern" vulnerability at transfer surfaces, integrating closed transfer, SIP sterilisation and EU GMP Annex 1 compliance into a single connection point without the need for a complex cleanroom infrastructure
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Japanese researchers report advances in liver disease treatment and cancer screening Two research teams in Japan have published findings that could open new avenues in metabolic disease treatment and non-invasive cancer screening

Upcoming event

CPhI Milan

6–8 October 2026 | Exhibition | Fiera Milano, Italy See all

You may also like

Manufacturing
DFE Pharma to showcase its Continuous Manufacturing Platform at CPHI Milan 2026

DFE Pharma to showcase its Continuous Manufacturing Platform at CPHI Milan 2026

The platform supports pharmaceutical companies in developing, evaluating and optimising formulations and processes for continuous manufacturing
Manufacturing
Enzene: Bringing the most advanced innovations to biologics manufacturing

Enzene: Bringing the most advanced innovations to biologics manufacturing

Enzene is a CIDMO partner supporting innovators and biosimilar developers from discovery to commercial supply with integrated, paradigm-changing biologics services and technologies, including EnzeneX and NeX
Research & Development
Oncodesign Services and Nexus BioQuest partner on preclinical drug development

Oncodesign Services and Nexus BioQuest partner on preclinical drug development

The collaboration combines human-relevant in vitro immunology with in vivo pharmacology to support biotech drug discovery programmes, including endometriosis research
Manufacturing
Upperton gains MHRA licence for Annex 1-aligned sterile facility

Upperton gains MHRA licence for Annex 1-aligned sterile facility

UK CDMO Upperton can now manufacture sterile investigational medicinal products at its new 7,000 sq ft facility in Nottingham, expanding its GMP clinical supply capabilities
Pharma 5.0
Beyond drug discovery: the untapped value of AI in pharma operations

Beyond drug discovery: the untapped value of AI in pharma operations

The next phase of AI adoption in pharma could be less about discovering new medicines and more about tackling the operational barriers that prevent AI projects from scaling, says Chu Canh Chieu, Vice President and Head of Healthcare & Life Sciences at FPT Corporation
Manufacturing
Beyond containment: integrated line design reduces risk and complexity

Beyond containment: integrated line design reduces risk and complexity

As demand for HPAPIs and highly potent drug products grows, the pharmaceutical industry faces increasing pressure to combine containment, product and operator protection, regulatory compliance and operational efficiency in fill-finish manufacturing. Success depends on a seamless line that addresses these challenges with one holistic solution
Manufacturing
Anton Paar’s popular viscosity workshop returns to Luton this October

Anton Paar’s popular viscosity workshop returns to Luton this October

Free in-person workshop combines expert theory with hands-on laboratory sessions to build confidence in viscosity measurement
Subscribe now